# OnCo record bispecific-step-up-dosing (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/bispecific-step-up-dosing/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "bispecific-step-up-dosing" ;
  schema:name "T-cell engaging bispecific antibodies: step-up dosing, monitoring and outpatient delivery"@en ;
  schema:alternateName "bispecific step-up dosing"@en, "BCMA bispecific outpatient dosing"@en, "teclistamab step-up"@en, "elranatamab step-up"@en, "bispecific CRS prevention"@en, "T-cell engager monitoring"@en ;
  schema:description "Bispecific antibodies such as teclistamab and elranatamab for myeloma, or glofitamab and epcoritamab for lymphoma, link T cells to cancer cells. The first doses are built up in steps to lower the risk of cytokine release syndrome (fever, low blood pressure) and confusion. Some countries do this in hospital; others let chosen patients go home between doses with a trained carer and a 24-hour number."@en ;
  schema:url <https://onco.cc/protocols/bispecific-step-up-dosing/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  onco:tag "protocol", "cell-therapy", "bispecific" ;
  onco:related <https://onco.cc/protocols/crs-grading-and-management/>, <https://onco.cc/protocols/icans-grading-and-management/> ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:drugs <https://onco.cc/drugs/teclistamab/>, <https://onco.cc/drugs/elranatamab/>, <https://onco.cc/drugs/linvoseltamab/>, <https://onco.cc/drugs/talquetamab/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/mosunetuzumab/>, <https://onco.cc/drugs/tocilizumab/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/human-normal-immunoglobulin/> ;
  onco:terms <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/>, <https://onco.cc/terms/lymphoma-tx-bispecific-step-up/>, <https://onco.cc/terms/lymphoma-tx-immunoglobulin-replacement/> .